Z
9.23
-0.17 (-1.81%)
| Previous Close | 9.40 |
| Open | 9.41 |
| Volume | 1,201,621 |
| Avg. Volume (3M) | 1,914,821 |
| Market Cap | 519,626,240 |
| Price / Earnings (TTM) | 19.64 |
| Price / Earnings (Forward) | 15.82 |
| Price / Sales | 6.24 |
| Price / Book | 3.98 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Profit Margin | -226.64% |
| Operating Margin (TTM) | -26.28% |
| Diluted EPS (TTM) | -1.94 |
| Quarterly Revenue Growth (YOY) | 495.70% |
| Total Debt/Equity (MRQ) | 150.74% |
| Current Ratio (MRQ) | 3.02 |
| Operating Cash Flow (TTM) | -61.72 M |
| Levered Free Cash Flow (TTM) | -39.23 M |
| Return on Assets (TTM) | -27.73% |
| Return on Equity (TTM) | -204.78% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Zevra Therapeutics, Inc. | Bearish | Bullish |
AIStockmoo Score
0.9
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.88 |
|
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.69% |
| % Held by Institutions | 65.42% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Stonepine Capital Management, Llc | 30 Sep 2025 | 810,000 |
| Velan Capital Investment Management Lp | 30 Jun 2025 | 715,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 24.00 (Cantor Fitzgerald, 160.02%) | Buy |
| 24.00 (Canaccord Genuity, 160.02%) | Buy | |
| Median | 24.00 (160.02%) | |
| Average | 24.00 (160.02%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 9.09 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 06 Nov 2025 | 24.00 (160.02%) | Buy | 9.09 |
| Cantor Fitzgerald | 06 Nov 2025 | 24.00 (160.02%) | Buy | 9.09 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |